Coya Therapeutics

ALS News Today highlighted 2024's top ALS research, including TPN-101's Phase 2a success, IGFBP7 gene's link to ALS reversal, COYA 302's promise, SPG302's FDA clearance, Japan's high-dose B12 approval, Prilenia's Phase 3 plans, recreational activities' ALS risk, Relyvrio's discontinuation, monepantel's potential, and PrimeC's survival benefits.

Coya Therapeutics enrolled 5 of 8 FTD patients in a Phase 1 study evaluating LD IL-2 + CTLA4-Ig's safety, Treg cell populations, and FTD progression. Results will inform a Phase 2 trial of COYA 302, supported by a $5M ADDF grant.

Coya Therapeutics appointed Arun Swaminathan as CEO, replacing co-founder Howard Berman, who became executive chairman. Swaminathan, previously chief business officer, aims to maintain visibility and continue Berman's legacy. Coya focuses on Alzheimer's treatments using T regs, with strong ties to Houston Methodist.

Weekend warrior activity linked to lower dementia risk; physical activity post-dementia diagnosis reduces mortality; deferiprone worsens early Alzheimer's; bepranemab shows mixed results; LX1001 improves APOE2 and tau biomarkers; low-dose interleukin-2 safe in Alzheimer's; out-of-pocket costs for neuro drugs rise; autism diagnoses increase; Alzheimer's GWAS data criticized; NHLPA forms CTE advisory committee; debate on reporting medically impaired drivers.

Eli Lilly's Q3 sales of GLP-1 drugs Mounjaro and Zepbound missed analyst projections, leading to a stock decline and lowered revenue guidance for 2024. Despite strong underlying growth, factors like inventory cuts and 'lumpiness' in stocking contributed to the shortfall. Lilly plans to boost marketing efforts for the drugs.

S.P. reports research grants and consulting fees from various pharmaceutical companies and organizations. M.C. reports consulting fees and institutional research support from multiple entities and serves on the board of Praxis. B.H. and E.G. report no competing interests.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

Coya Therapeutics to discuss Phase 2 trial results of LD IL-2 in Alzheimer’s patients on Oct 29, 2024, at 8am ET, with a webcast available. The trial, funded by Alzheimer’s Association, Gates Foundation, and National Institute on Aging, was led by Dr. Alireza Faridar and Dr. Stanley Appel.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.